Roche

News

Roche bags EU okay for subcutaneous Tecentriq

Roche has been given EU approval for a new formulation of its cancer immunotherapy Tecentriq that aims to make dosing easier for patients, nurses, and physicians.

News

Roche antibiotic tackles serious drug-resistant pathogen

Scientists at Roche and Harvard University have discovered an entirely new class of antibiotic that can kill a highly drug-resistant ‘superbug’ with a mortality rate that can be upwar

News

Roche bolsters diagnostics with $295m LumiraDx deal

A flurry of mergers and acquisitions in the pharma space at the end of 2023 ended with a $295 million deal by Roche to buy a point-of-care diagnostics platform from Lumira

News

Genentech confirms Magargee as permanent CEO

Roche’s Genentech unit has looked internally for its new chief executive, appointing Ashley Magargee to the role following the departure of Alexander Hardy last month.

News

Merck pummelled as MS hope evobrutinib dies in phase 3

Germany’s Merck KGaA is facing a big hole in its late-stage pipeline after multiple sclerosis (MS) candidate evobrutinib missed the mark in two phase 3 trials, spelling th

News

Roche bounces back in PIK3 with inavolisib data

A few years ago, Roche abandoned the development of its lead PIK3CA-targeting drug taselisib on safety grounds, allowing rival Novartis to beat it to market, but now it ha

Roche bags EU okay for subcutaneous Tecentriq

Roche antibiotic tackles serious drug-resistant pathogen

Roche bolsters diagnostics with $295m LumiraDx deal

Genentech confirms Magargee as permanent CEO

Merck pummelled as MS hope evobrutinib dies in phase 3

Roche bounces back in PIK3 with inavolisib data

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Roche

Editor's Picks